NCL Technology Ventures

Ampersand Health is focused on developing digital therapeutics for individuals with long-term inflammatory conditions. Based in London and incorporated in 2014, the company offers a comprehensive digital platform that includes the Ampersand Healthsuite, a management tool designed for patients, and Healthsuite for Clinicians, which supports clinician-led, patient-centered self-management. The platform utilizes behavioral science to deliver personalized therapy, featuring expert-led courses, self-management tracking, and clinical messaging. Ampersand Health aims to enhance patients' mental health and quality of life while also providing significant cost savings for healthcare providers by reducing overall healthcare utilization.

Founded in 2017, Curesponse is a diagnostics company based in Tel Aviv-Yafo, Israel. It develops a three-dimensional tissue culture system for modelling cancer growth and drug response, preserving the cancer's original microenvironment. The company offers an online platform enabling patients and clinicians to send tumor samples for testing, aiming to improve personalized cancer treatment by matching the most effective drugs to individual patients' tumors.

Ampersand Health is focused on developing digital therapeutics for individuals with long-term inflammatory conditions. Based in London and incorporated in 2014, the company offers a comprehensive digital platform that includes the Ampersand Healthsuite, a management tool designed for patients, and Healthsuite for Clinicians, which supports clinician-led, patient-centered self-management. The platform utilizes behavioral science to deliver personalized therapy, featuring expert-led courses, self-management tracking, and clinical messaging. Ampersand Health aims to enhance patients' mental health and quality of life while also providing significant cost savings for healthcare providers by reducing overall healthcare utilization.

Founded in 2015, Emteq develops advanced facial wearables that interpret expressions and emotions using AI. Its products enable improved Human-Computer Interaction, Human Augmentation, and Emotion Analytics.

Azadyne is a biotechnology company that specializes in innovative RNA modification technologies aimed at treating autoimmune diseases. The company’s approach is based on research conducted at Trinity College, focusing on an unexplored pathway in the body to increase regulatory T cell levels. By selectively controlling natural regulatory pathways, Azadyne seeks to modify specific pathogenic immune populations, providing patients with effective treatments for various autoimmune conditions.

Founded in 2011, Revolo Biotherapeutics specializes in developing therapies for autoimmune and allergic diseases. Its innovative approach aims to achieve superior long-term remission with less frequent dosing, without suppressing the immune system.

Sana Health, Inc. is a digital health company based in Lafayette, Colorado, with an additional office in Mill Valley, California. Founded in 2015, the company specializes in developing bio-therapeutic devices designed to promote relaxation and alleviate pain and tension. Its flagship product, Sana, is a non-addictive mask and headphone combination that utilizes audiovisual stimulation to enhance the balance between the left and right sides of the brain, facilitating a deep meditative state. This device employs coordinated pulses of light and sound to guide users into relaxation, mimicking the benefits of long-term meditation practices. Sana Health is also engaged in multiple clinical studies, focusing on applications for conditions such as fibromyalgia and neuropathic pain, as well as trials related to anxiety and PTSD. The company offers its products for sale online and provides a mobile application accessible via major app platforms.

Andiamo is a custom medical wearables platform that focuses on providing innovative solutions for neuromuscular conditions, beginning with cerebral palsy. The company operates a digital clinic that connects families with specialists, ensuring they receive the necessary care and expertise when and where it is needed. By leveraging technology, Andiamo aims to improve the quality of life for individuals with neuromuscular disorders through tailored wearable devices and specialized medical services.

Peptinnovate Ltd is a drug development company focused on researching and developing immune-regulating therapies for conditions such as asthma, atopic dermatitis, and inflammatory bowel disease. Established in 2011 and headquartered in Stevenage, United Kingdom, the company utilizes innovative biotechnology inspired by the mechanisms employed by Mycobacterium tuberculosis to evade the host's immune system and modulate inflammatory responses. Peptinnovate aims to advance treatment options for various immuno-inflammatory diseases through its targeted therapeutic approaches.

Coomtech Ltd. is a sustainable energy technology company based in Sandwich, United Kingdom, established in 2011. The company specializes in developing innovative technologies for drying and upgrading coal and biomass, aiming to enhance the efficiency of the combustion process. Coomtech's offerings include surface moisture removal technology, which employs high-velocity air to eliminate moisture from coal particles, and inherent moisture removal technology that utilizes a hydrothermal treatment for multi-stage drying. These advanced processes not only reduce energy costs and emissions but also provide significant cost savings for industrial operations. Coomtech collaborates with various strategic partners, including Narec Capital Ltd. and the University of Greenwich Wolfson Centre, to further its mission in improving plant efficiency and promoting sustainable practices within the construction and renewable energy sectors.

TC Biopharm Limited is a clinical development company based in Edinburgh, United Kingdom, that specializes in the development, manufacturing, and commercialization of innovative cell-based products aimed at treating cancer and severe viral infections. The company’s flagship product, ImmuniCell, is an autologous therapy that expands patient-derived cells in a cleanroom environment to create treatments for various tumor types and viral infections. TC Biopharm is advancing its pipeline through Phase II/III clinical studies, focusing on conditions such as renal cell carcinoma, non-small cell lung cancer, and melanoma. The company is committed to developing safer, more effective, and durable therapies, utilizing its proprietary allogeneic gamma delta T cell platform to harness the innate immune response against malignancies and infections. Through strategic partnerships and collaborations with organizations like Medinet and bluebird bio, TC Biopharm aims to enhance its capabilities and accelerate the delivery of its therapies to patients.

Centauri Therapeutics is a biotechnology company that develops novel immunotherapeutics employing a dual‑mechanism platform. Its molecules combine a cell‑surface antigen‑binding moiety with a glycan effector domain that harnesses the body’s pre‑existing polyclonal antibodies. This design amplifies complement fixation, antibody‑dependent cellular cytotoxicity, and phagocytosis, enabling targeted cell death. The company’s pre‑clinical studies demonstrate potent enhancement of complement fixation and opsonophagocytosis for both antibacterial and oncology agents, and in vivo proof of concept in multiple infection models. Centauri also utilizes alphamer technology, chemically synthesizing molecules that redirect endogenous antibodies to specific pathogens, providing a new approach to treating infectious diseases. The company focuses on life‑threatening conditions, aiming to bring innovative therapies to patients.